MMP9 Inhibitor Screening Assay Kit (Fluorometric) (ab139449)


  • Product name
    MMP9 Inhibitor Screening Assay Kit (Fluorometric)
    See all MMP9 kits
  • Detection method
  • Sample type
    Inhibitor compounds
  • Assay type
    Enzyme activity
  • Product overview

    Abcam MMP9 Inhibitor Screening Assay Kit (Fluorometric) (ab139449) is a complete assay system designed to screen MMP9 inhibitors using a quenched fluorogenic peptide: MMP Fluorogenic Substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 [Mca=(7-methoxycoumarin-4-yl)-acetyl; Dpa=N-3-(2,4-dinitrophenyl)-L-α-β-diaminopropionyl]. Mca fluorescence is quenched by the Dpa group until cleavage by MMPs at the Gly-Leu bond separates the two moieties. The assays are performed in a convenient 96-well microplate format.

  • Notes

    This kit is useful to screen inhibitors of MMP9, a potential therapeutic target. The MMP inhibitor NNGH is also included as a prototypic control inhibitor.

  • Platform
    Microplate reader


  • Storage instructions
    Please refer to protocols.
  • Components 1 x 96 tests
    96-well White Microplate 1/2 Volume 1 unit
    Fluorometric Assay Buffer 1 x 20ml
    MMP Calibration Standard 1 x 50µl
    MMP Fluorogenic Substrate 1 x 200µl
    MMP Inhibitor 1 x 50µl
    MMP9 Enzyme (Human, Recombinant) 1 x 48.5µl
  • Function
    May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-
    -Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
  • Tissue specificity
    Produced by normal alveolar macrophages and granulocytes.
  • Involvement in disease
    Defects in MMP9 may be a cause of susceptibility to intervertebral disc disease (IDD) [MIM:603932]; also known as lumbar disk herniation (LDH). IDD is one of the most common musculo-skeletal disorders and the predominant cause of low-back pain and unilateral leg pain.
    Defects in MMP9 are the cause of metaphyseal anadysplasia type 2 (MANDP2) [MIM:613073]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
  • Sequence similarities
    Belongs to the peptidase M10A family.
    Contains 3 fibronectin type-II domains.
    Contains 4 hemopexin-like domains.
  • Domain
    The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
  • Post-translational
    Processing of the precursor yields different active forms of 64, 67 and 82 kDa. Sequentially processing by MMP3 yields the 82 kDa matrix metalloproteinase-9.
    N- and O-glycosylated.
  • Cellular localization
    Secreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Alternative names
    • 82 kDa matrix metalloproteinase-9
    • 92 kDa gelatinase
    • 92 kDa type IV collagenase
    • Gelatinase B
    • GELB
    • MMP-9
    • MMP9
    • MMP9_HUMAN
    see all


  • Inhibiton of MMP9 by NNGH.



ab139449 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab139449.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact

Sign up